TY  - JOUR
AU  - Owonikoko, Taofeek K
AU  - Park, Keunchil
AU  - Govindan, Ramaswamy
AU  - Ready, Neal
AU  - Reck, Martin
AU  - Peters, Solange
AU  - Dakhil, Shaker R
AU  - Navarro, Alejandro
AU  - Rodríguez-Cid, Jerónimo
AU  - Schenker, Michael
AU  - Lee, Jong-Seok
AU  - Gutierrez, Vanesa
AU  - Percent, Ivor
AU  - Morgensztern, Daniel
AU  - Barrios, Carlos H
AU  - Greillier, Laurent
AU  - Baka, Sofia
AU  - Patel, Miten
AU  - Lin, Wen Hong
AU  - Selvaggi, Giovanni
AU  - Baudelet, Christine
AU  - Baden, Jonathan
AU  - Pandya, Dimple
AU  - Doshi, Parul
AU  - Kim, Hye Ryun
PY  - 2021
DO  - 10.1200/JCO.20.02212
UR  - http://hdl.handle.net/10668/17328
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Ipilimumab
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Nivolumab
KW  - Small Cell Lung Carcinoma
TI  - Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
TY  - research article
VL  - 39
ER  -